Loading...
Docoh

Zynerba Pharmaceuticals (ZYNE)

News

From Benzinga Pro
Marijuana Stock Movers For May 18, 2022
18 May 22
Cannabis, Markets, Movers
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 21.21% at $1.00
Cannabis Stock Gainers And Losers From May 17, 2022
17 May 22
Cannabis, Markets, Movers
GAINERS: cbdMD (AMEX:YCBD) shares closed up 11.63% at $0.76
Cannabis Stock Gainers And Losers From May 16, 2022
16 May 22
Cannabis, Markets, Movers
GAINERS: Sundial Growers (NASDAQ:SNDL) shares closed up 21.09% at $0.47
Zynerba Pharmaceuticals R&D Expenses Reach $5.1M For Q1 2022, Here Are The Details
16 May 22
Cannabis, Earnings, News, Penny Stocks, Markets
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million.
Recap: Zynerba Pharmaceuticals Q1 Earnings
16 May 22
Earnings, News
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Zynerba Pharmaceuticals Q1 EPS $(0.21) Down From $(0.20) YoY
16 May 22
Earnings, News
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.21) per share. This is a 5 percent decrease over losses of $(0.20) per share from the same period last year.
Cannabis Stock Movers For May 11, 2022
11 May 22
Cannabis, Markets, Movers
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 28.38% at $0.02
Zynerba Pharmaceuticals Presents Long-Term Safety And Efficacy Data Of Zygel In Children And Adolescents With Fragile X Syndrome At The International Society For Autism Research Annual Meeting
11 May 22
News, FDA
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting an oral podium
Stocks That Hit 52-Week Lows On Wednesday
11 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Wednesday, 807 companies reached new 52-week lows.
Cannabis Stock Gainers And Losers From May 10, 2022
10 May 22
Cannabis, Markets, Movers
GAINERS: Cara Therapeutics (NASDAQ:CARA) shares closed up 23.76% at $9.22
Marijuana Stock Movers For May 9, 2022
9 May 22
Cannabis, Markets, Movers
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 9.00% at $1.09
Cannabis Stock Movers For May 6, 2022
6 May 22
Cannabis, Markets, Movers
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 13.33% at $0.02
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Cannabis Stock Movers For May 5, 2022
5 May 22
Cannabis, Markets, Movers
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 8.62% at $0.01
Bearish Sentiment Across The Cannabis Space - Check Full Movers For May 3, 2022
3 May 22
Cannabis, Markets, Movers
GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 5.91% at $0.02
Bullish Sentiment Across The Cannabis Space - Check Full Movers For May 2, 2022
2 May 22
Cannabis, Markets, Movers
GAINERS: GrowGeneration (NASDAQ:GRWG) shares closed up 9.14% at $6.45
12 Health Care Stocks Moving In Friday's After-Market Session
29 Apr 22
Movers
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Marijuana Stock Movers For April 26, 2022
26 Apr 22
Cannabis, Markets, Movers
GAINERS: LOSERS: Leviathan Natural Prods (OTC:LVCNF) shares closed down 13.22% at $0.66

Press releases

From Benzinga Pro
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
17 May 22
News, Press Releases
DEVON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
11 May 22
Health Care, Press Releases
– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Zynerba
Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
9 May 22
News, Health Care, Press Releases, General
DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
1 Mar 22
Earnings, Press Releases
– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
28 Feb 22
Health Care, Press Releases
DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric